Generics, OTC AND API Groups Object To Proposed US Tariffs On Goods From China

Organizations representing generic and over-the-counter drug manufacturers and active pharmaceutical ingredient suppliers have registered their opposition to the Trump administration’s proposed 25% tariffs on pharmaceutical products and active ingredients from China.

Meanwhile, groups representing brand pharmaceutical and biotechnology manufacturers have remained silent on the proposed tariffs, although the brand pharmaceutical sector has recently criticized emerging economies like China and India for...